Actinium Pharmaceuticals/ATNM

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing targeted radiotherapies to improve survival for people who have failed existing oncology therapies. The Company’s advanced pipeline candidates include Iomab-B (pre-BLA & MAA (EU)) and Actimab-A. Iomab-B is an induction and conditioning agent prior to bone marrow transplant. Actimab-A is a therapeutic agent, have demonstrated potential to extend survival outcomes for people with relapsed and refractory acute myeloid leukemia. The Company focuses on advance Iomab-B for other blood cancers and next generation conditioning candidate Iomab-ACT to improve cell and gene therapy outcomes. The Company holds patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron. Actinium-225 is a potent alpha-particle emitter that has high linear energy transfer capable of killing targeted cancer cells via double-strand breaks in DNA.

Ticker

ATNM

Sector

Healthcare

Trading on

AMEX

Industry

Biotechnology & Drugs

CEO

Sandesh Seth

Employees

49

Headquarters

New york, United States

ATNM Metrics

BasicAdvanced
$243M
Market cap
-
P/E ratio
-$1.72
EPS
0.12
Beta
-
Dividend rate
$243M
0.11956
$10.24
$4.00
398K
10.587
0.039
0.064
-48.80%
-91.92%
-53.25%
2,996.73
5.463
5.535
-10.00%
-10.93%

What the Analysts think about ATNM

Analyst Ratings

Majority rating from 7 analysts.
Buy

ATNM Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$8.6M
-7.53%
Profit margin
0.00%
NaN%

ATNM Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 40.38%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.58
-$0.49
-$0.34
-$0.31
-
Expected
-$0.48
-$0.53
-$0.54
-$0.52
-$0.41
Surprise
20.83%
-7.84%
-37.04%
-40.38%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Actinium Pharmaceuticals stock?

Actinium Pharmaceuticals (ATNM) has a market cap of $243M as of June 18, 2024.

What is the P/E ratio for Actinium Pharmaceuticals stock?

The price to earnings (P/E) ratio for Actinium Pharmaceuticals (ATNM) stock is 0 as of June 18, 2024.

Does Actinium Pharmaceuticals stock pay dividends?

No, Actinium Pharmaceuticals (ATNM) stock does not pay dividends to its shareholders as of June 18, 2024.

When is the next Actinium Pharmaceuticals dividend payment date?

Actinium Pharmaceuticals (ATNM) stock does not pay dividends to its shareholders.

What is the beta indicator for Actinium Pharmaceuticals?

Actinium Pharmaceuticals (ATNM) has a beta rating of 0.12. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Actinium Pharmaceuticals stock price target?

The target price for Actinium Pharmaceuticals (ATNM) stock is $25.4, which is NaN% below the current price of $. This is an average based on projections from 7 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Actinium Pharmaceuticals stock

Buy or sell Actinium Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing